3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
21
pembrolizumab
17
Capecitabine
15
Nivolumab
13
Paclitaxel
12
Fluorouracil
12
Leucovorin
11
Docetaxel
10
atezolizumab
7
Trastuzumab
7
tislelizumab
5
Ramucirumab
5
durvalumab
4
Standard of Care
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Cisplatin
4
Carboplatin
4
zolbetuximab
3
zimberelimab
3
apatinib
3
Specimen Handling
3
S 1 (combination)
3
Gemcitabine
3
Bevacizumab
3
trifluridine tipiracil drug combination
2
tremelimumab
2
trastuzumab deruxtecan
2
relatlimab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Stomach Neoplasms
×
zanidatamab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled